GBM-I responds to therapies targeting EGFR, such as Temozolomide (TMZ), and monoclonal antibodies like bevacizumab [25], while GBM-II is susceptible to chemoradiotherapy and Bcl-xL inhibitors [24]. Here, EGFR is linked to glioblastoma.